Varicose veins affect millions worldwide, causing both cosmetic concerns and potential health
complications. In recent years, a groundbreaking treatment called CLACS (Cryo-Laser and
Cryo-Sclerotherapy) has emerged as a game-changer in vascular medicine, offering new hope to
patients seeking effective, minimally invasive solutions.
CLACS, developed by Dr. Kasuo Miyake in Brazil, represents a significant advancement in vein therapy. This innovative treatment combines the precision of laser therapy with the effectiveness of sclerotherapy, while incorporating cryotherapy for enhanced patient comfort. Unlike traditional surgical approaches, CLACS specifically targets spider veins and small varicose veins with remarkable precision.
Recent research has demonstrated impressive outcomes for CLACS treatment. Studies conducted at the Federal University of São Paulo have shown superior vein clearance compared to conventional sclerotherapy. A comprehensive European multicentre study has reported sustained results with minimal recurrence over a five-year follow-up period. The University of São Paulo’s safety-focused research has further confirmed CLACS’s favorable safety profile, documenting minimal complications.
The CLACS procedure typically takes 30-60 minutes and follows a systematic approach:
• Initial consultation and vein assessment
• Application of cryotherapy for local numbing
• Initial consultation and vein assessment
• Precise vein mapping using transdermal vein light or ultrasound
• Many insurers cover varicose vein treatments deemed medically necessary,but
coverage for VenaSeal® varies.
CLACS offers several distinct advantages:
• Minimally invasive nature reduces recovery time
• Enhanced comfort through cold air application
• High success rates in treating superficial veins
• Quick return to daily activities
• Reduced risk of complications
As CLACS continues to gain recognition worldwide, its adoption in various countries, including
India, demonstrates its potential to revolutionize varicose vein treatment. The combination of
high efficacy rates, minimal invasiveness, and patient comfort makes it an attractive option for
both practitioners and patients.
The treatment’s success in clinical studies, coupled with positive long-term outcomes, suggests
that CLACS may become the gold standard for treating superficial venous conditions. However, as
with any medical procedure, consultation with a qualified vascular specialist remains essential
for determining the most appropriate treatment approach for individual cases.
For patients seeking a balance between effective treatment and minimal downtime, CLACS
represents a significant advancement in vascular medicine. As research continues and techniques
are refined, this innovative approach promises to remain at the forefront of modern vein
therapy.
For any unanswered questions, reach out to our support team via email. We’ll respond as soon as possible to assist you.